Ning, D
McKenzie SJ, Baker MS, Buffinton GD, and Doe WF (1996)
Oncotarget 11 , 44904503 (2020)
The published menu spans 15+ compounds, which is unusually deep for a non-metro market
Published in Pharmaceuticals by Sikiric and colleagues, the comprehensive review synthesizes decades of preclinical research demonstrating BPC-157s remarkable ability to modulate dopaminergic, serotonergic, glutamatergic, GABAergic, and nitric oxide systems simultaneously
Better understanding of the mechanism and TGR/TrxR reduced species involved in the binding of inhibitors depending on microenvironment may offer an additional avenue to control inhibitor selectivity in organism, tissue, and cell type specific manner